June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Significantly reduced level of lymphotoxin-alpha (LTA) in tears from dry eye patients with Sjogren’s syndrome or other systemic immune disease detected with a Point-of-Care LTA test
Author Affiliations & Notes
  • Jing-Feng Huang, PhD
    Seinda Biomedical Corporation, Guangzhou, China
  • He Li
    Seinda Biomedical Corporation, Guangzhou, China
    Bioisland Laboratory, China
  • Liang Li
    Seinda Biomedical Corporation, Guangzhou, China
  • Angela Y. Xiao
    Seinda Biomedical Corporation, Guangzhou, China
  • Cong Liao
    Seinda Biomedical Corporation, Guangzhou, China
  • Ying Li
    Xi'an People's Hospital Shaanxi Eye Hospital, Xi'an, Shaanxi, China
  • Footnotes
    Commercial Relationships   Jing-Feng Huang, PhD None; He Li None; Liang Li None; Angela Y. Xiao None; Cong Liao None; Ying Li None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 3946. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jing-Feng Huang, PhD, He Li, Liang Li, Angela Y. Xiao, Cong Liao, Ying Li; Significantly reduced level of lymphotoxin-alpha (LTA) in tears from dry eye patients with Sjogren’s syndrome or other systemic immune disease detected with a Point-of-Care LTA test. Invest. Ophthalmol. Vis. Sci. 2023;64(8):3946.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : This study aimed to measure and compare the LTA levels in tears from dry eye disease (DED) patients with systemic immune disease (ID) and DED without, and to examine the role and clinical value of LTA in early diagnosis of DED associated with ID. LTA (also known as LTa3), the secreted soluble homotrimeric form of Lymphotoxin-alpha, is a cytokine that performs a variety of important roles in immune regulation.

Methods : An observational study consecutively enrolled moderate to severe DED patients with or without Sjogren’s syndrome (SS) or other ID at the Xi’an People’s Hospital (Xi'an, China) from March to July 2022. The Ocular Surface Disease Index (OSDI) and Ocular discomfort score (ODS), conjunctival hyperemia, eyelid margin morphology assessment (EMMA), Schirmer’s test (STT), non-invasive tear breakup time (NITBUT), tear meniscus height (NITMH), corneal fluorescein staining (CFS), and conjunctival lissamine green staining (LGS) were also conducted. The LTA levels were measured with a Point-of-Care (POC) LTA test kit on-site and compared across different DED groups. Correlations with DED clinical parameters were also examined.

Results : This study enrolled a total of 80 patients, 44 of which had SS or other ID and 36 of which did not. The DED patients with SS or ID exhibited significantly lower STT (3.61 (95% CI: 2.53-4.70), 7.58 (5.45-9.72), P<0.001), shorter NITBUT (4.57 (3.59-5.54), 9.06 (7.56-10.57) p<0.001), more conjunctival hyperemia (p<0.001), higher EMMA score (P<0.001), higher CFS (p<0.001) and LGSC (P<0.001), worse ODS (p<0.05), and worse visual acuity (p<0.01). Importantly, in the DED group with SS or ID, LTA levels in tears were significantly lower (169.82 vs. 331.13 pg/ml, p<0.01) than the DED group without. Moreover, the LTA level was significantly negatively correlated with CFS (correlation coefficient (r): -0.447, P<0.001) and EMMA score (r: -0.317, P=0.01).

Conclusions : Previously tear LTA was found reduced in DED compared with normal. Here LTA levels in DED with SS or ID were remarkably lower than in DED patients without. The level of LTA was significantly inversely correlated with the severity of ocular surface damage. Thus, a POC LTA test may have clinical value as an indicator to reflect DED severity and serve as an early diagnostic marker for SS or ID-associated dry eye.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×